الصفحة الرئيسية>>Signaling Pathways>> Tyrosine Kinase>> FGFR>>Rogaratinib (BAY1163877)

Rogaratinib (BAY1163877)

رقم الكتالوجGC34067

روجاراتينيب (BAY1163877) (BAY1163877) هو مثبط قوي وانتقائي لعامل نمو الخلايا الليفية (FGFR).

Products are for research use only. Not for human use. We do not sell to patients.

Rogaratinib (BAY1163877) التركيب الكيميائي

Cas No.: 1443530-05-9

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
424٫00
متوفر
1mg
138٫00
متوفر
5mg
414٫00
متوفر
10mg
597٫00
متوفر
50mg
1792٫00
متوفر
100mg
2712٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Rogaratinib is a potent and selective fibroblast growth factor receptor (FGFR) inhibitor.

Of the 24 cell lines, 2 FGFR1-amplified lung cancer (LC) cell lines, H1581 and DMS114, show extreme sensitivity to Rogaratinib (BAY1163877) (GI50 values ranging from 36 to 244 nM). Treatment with Rogaratinib results in a significant decrease in colonies formed by H1581P cells, but not by H1581AR and BR cells. Ectopic expression of Met significantly induces resistance to Rogaratinib in MTT assays. Met overexpression induces activation of downstream extracellular signal-regulated kinase 1/2 (ERK1/2) and AKT, which cannot be abrogated by Rogaratinib treatment[1].

[1]. Kim SM, et al. Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy. Oncogenesis. 2016 Jul 18;5(7):e241.

مراجعات

Review for Rogaratinib (BAY1163877)

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Rogaratinib (BAY1163877)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.